Therapeutic application of peptides and proteins: parenteral forever?

Trends in Biotechnology

Volumn 27, Issue 11, 2009, Pages 628-635

  Antosova, Zuzana ^a,c   Mackova, Martina ^a,b   Kral, Vladimir ^a,c   Macek, Tomas ^a,b  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c Zentiva Prague   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BIODRUGS; BIOTECHNOLOGY INDUSTRY; DRUG DELIVERY SYSTEM; PATIENT COMPLIANCE; PHYSICOCHEMICAL PROPERTY; STABILIZING AGENTS; THERAPEUTIC APPLICATION; THERAPEUTIC PEPTIDES; TRANSDERMAL ADMINISTRATION;

BIOCHEMISTRY; DRUG DELIVERY; PEPTIDES;

AMINES;

AFRESA; ALPHA2B INTERFERON; BUSERELIN; BUSERELIN ACETATE; CORTICOTROPIN; DESMOPRESSIN; GONADORELIN; INSULIN; INTESULIN; LIPOTET; MACRULIN; PEPTIDE; PROTEIN; PROTIRELIN; RECOMBINANT HUMAN INSULIN; SALCATONIN; TETANUS TOXOID; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN;

CHEMICAL MODIFICATION; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CRYPTORCHISM; DIABETES INSIPIDUS; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MARKETING; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; ENDOMETRIOSIS; HUMAN; HYPERCALCEMIA; INFERTILITY; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULAR WEIGHT; NANOBIOTECHNOLOGY; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TETANUS; UTERINE CERVIX DYSPLASIA;

ANIMALS; BIOMEDICAL TECHNOLOGY; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; PEPTIDES; PROTEINS;

EID: 70349998626     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2009.07.009     Document Type: Review

References (70)

1. Walsh G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24 (2006) 769-776
2. Chrastilova Z., et al. Bioleciva - jaky je jejich skutecny potencial?. Chem. Listy 101 (2007) 25-35
3. Johnson-Léger C., et al. Protein therapeutics - lessons learned and a view of the future. Expert Opin. Biol. Ther. 6 (2006) 1-7
4. Semalty A., et al. Properties and formulation of oral drug delivery systems of protein and peptides. Indian J. Pharm. Sci. 69 (2007) 741-747
5. Singh R., et al. Past, present, and future technologies for oral delivery of therapeutic proteins. J. Pharm. Sci. 97 (2008) 2497-2523
6. Amsden B.G., and Goosen F.A. Transdermal delivery of peptide and protein drugs: an overview. AIChE J. 41 (1995) 1972-1997
7. Scheuch G., and Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptides. J. Physiol. Pharmacol. 58 (2007) 615-625
8. Langer R., et al. Controlled release of macromolecules: biological studies. J. Cont. Rel. 2 (1985) 331-341
9. Humphrey M.J., and Ringrose P.S. Peptide and related drugs: A review of their absorption, metabolism and excretion. Drug. Metab. Rev. 17 (1986) 283-310
10. McMartin C., et al. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76 (1987) 535-540
11. Donovan M.D., et al. Absorption of polyethylene glycols 600 through 2000: The molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. 7 (1990) 863-868
12. Tsai P.K. Formulation design of acidic fibroblast growth factor. Pharm. Res. 10 (1993) 649-659
13. Johnson O.L., et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. 2 (1996) 795-799
14. Charman S.A., et al. Techniques for assessing the effects of pharmaceutical recipients on aggregation of porcine growth hormone. Pharm. Res. 10 (1993) 954-962
15. Carino G.P., and Mathiowitz E. Oral insulin delivery. Adv. Drug Deliv. Rev. 35 (1999) 249-257
16. Burnham N. Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 51 (1994) 210-218
17. Sanvicens N., and Marco M.P. Multifunctional nanoparticles - properties and prospects for their use in human medicine. Trends Biotechnol. 26 (2008) 425-433
18. Gelperina S., et al. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med. 172 (2005) 1487-1490
19. Lee V.H.L. Changing needs in drug delivery in the era of peptide and protein drugs. In: Lee V.H.L. (Ed). Peptide and Protein Drug Delivery (1991), Marcel Dekker 1-56
20. Tauber U. Drug metabolism in the sk. In: advantages disadvantages., In: Hadgraft J., and Guy R.H. (Eds). Transdermal Drug Delivery (1989), Marcel Dekker 99-112
21. Bungaard H. The utility of a prodrug approach to improve peptide absorption. J. Control. Release 21 (1992) 63-72
22. Møss J., and Bungaard H. Prodrugs of peptides. 7. Transdermal delivery of thyreotropin releasing hormone (TRH) via prodrugs. Int. J. Pharm 66 (1990) 39-45
23. Walters K.A. Penetration enhancers and their use in transdermal therapeutic systems. In: Hadgraft J., and Guy R.H. (Eds). Transdermal Drug Delivery (1989), Marcel Dekker 197-233
24. Goodman M., and Barry B.W. Action of penetration enhancers of human stratum corneum as assessed by differential scanning calorimetry. In: Bronaugh R.L., and Maibach H.I. (Eds). Percutaneous Absorption. 2nd edn (1989), Marcel Dekker 567-595
25. Kastin A.J., et al. Topical absorption of polypeptides with dimethylsulfoxide. Arch. Dermatol. 93 (1996) 471-473
26. Hoogstraate A.J., et al. Kinetics, ultrastructural aspects and molecular modelling of transdermal peptide flux enhancement by N-alkylazacycloheptanones. Int. J. Pharm. 76 (1991) 37-47
27. Tachibana K., and Tachibana S. Transdermal delivery of insulin by ultrasonic vibration. J. Pharm. Pharmacol. 43 (1991) 270-271
28. Sowers A.E. Mechanisms of electroporation and electrofusion. In: Chang D.C., Saunders J.A., Chassy B.M., and Sowers A.E. (Eds). Guide to Electroporation and Electrofusion (1992), Academic Press 119-138
29. Srinivasan V., et al. Iontophoresis of polypeptides: effect of ethanol pretreatment of human skin. J. Pharm. Sci 79 (1990) 588-591
30. Meyer B.R., et al. Transdermal versus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect. Clin. Pharmacol. Ther. 48 (1990) 340-345
31. Banga A.K., and Chien Y.W. Hydrogel-based iontotherapeutic delivery devices for transdermal delivery of peptide/protein drugs. Pharm. Res. 10 (1993) 697-702
32. Riviere J.E., et al. Pulsatile transdermal delivery of LHRH using electroporation: drug delivery and skin toxicology. J. Control. Release 36 (1995) 229-233
33. Boddé H.E., et al. Transdermal peptide delivery. Biochem. Soc. Trans. 17 (1989) 943-945
34. King M.J., et al. Evidence for lymphatic transport of insulin by topically applied biphasic vesicles. J. Pharm. Pharmacol. 55 (2003) 1339-1344
35. Foldvari M., et al. Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha. Biotechnol. Appl. Biochem. 30 (1999) 129-137
36. Niven R.V. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 151-231
37. Wolff R.K. Safety of inhaled proteins for therapeutic use. J. Aerosol. Med. 11 (1998) 197-219
38. Labiris N.R., and Dolovich M.B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. J. Clin. Pharmacol 56 (2003) 588-599
39. Byron P.R. Determinants of drug and polypetide bio-availability from aerosols delivered to the lung. Adv. Drug Deliv Rev. 5 (1990) 107-132
40. Dolovich M. New propellant-free technologies under investigation. J. Aerosol Med. 12 (1999) S9-S17
41. ® Inhaled insulin system: a novel insulin-delivery system for patients with diabetes. Expert Rev. Med. Devices. 4 (2007) 683-692
42. Richardson P.C., and Boss A.H. Technosphere insulin technology. Diabetes Technol. Ther. 9 (2007) S65-S72
43. ® iDMS (Insulin Diabetes Management System) technology. Diabetes Technol. Ther. 9 (2007) S57-S64
44. Wall D.A., and Smith P.L. Inhalation therapy for growth hormone deficiency. In: Adjei J.A., and Gupta P.K. (Eds). Inhalation Delivery of Therapeutic Peptides and proteins (1997), Marcel Dekker 453-473
45. Pitt, C.G. and Platz, R.M. (1994) Amgen Inc. Pulmonary administration of erythropoietin, U.S. Patent 5354934
46. van Zandwijk N. Inhalation interferon. In: Adjei J.A., and Gupta P.K. (Eds). Inhalation Delivery of Therapeutic Peptides and Proteins (1997), Marcel Dekker 301-314
47. Laqueur E., and Grevenstuk A. Über die wirkung intratrachealer zuführung von insulin. Klin. Wochenschr. 328 (1924) 1273-1274
48. Heubner W., et al. Über inhalation von insulin. Klin. Wochenschr. 351 (1924) 2342-2343
49. Gänsslen M. Über inhalation von insulin. Klin. Wochenschr. 4 (1925) 71
50. Hite P.F., et al. Exhuberance over exhubera. Clin. Diabetes 24 (2006) 110-114
51. Ugwoke M.I., et al. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 53 (2001) 3-21
52. Shah S.H., et al. An overview on brain targeting drug delivery system. Pharm. Rev. (2009) 7
53. Dufes C., et al. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int. J. Pharm. 255 (2003) 87-97
54. David S.S., and Illum L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet. 42 (2003) 1107-1128
55. Türker S., et al. Nasal route and drug delivery systems. Pharm. World Sci. 26 (2004) 137-142
56. Kim D.-D. In vitro cellular models for nasal drug absorption studies. In: Ehrhardt C., and Kim K.-J. (Eds). Drug Absorption Studies: In Situ, In Vitro and In Silico Models (2008), Springer 216-230
57. Vegh A. Experiences with Kryptocur in the treatment of cryptorchism. Acta Chir. Hung. 28 (1987) 257-261
58. Peichl P., et al. Clinical outcome of salmon calcitonin nasal spray treatment in postmenopausal women after total hip arthroplasty. Gerontology 51 (2005) 242-252
59. Pauletti G., et al. Structural requirements for intestinal absorption of peptide dugs. J. Control. Release 41 (1996) 3-17
60. Mesiha M., et al. Enhanced oral absorption of insulin from desolvated fatty acid - sodium glycocholate emulsions. Int. J. Pharm. 111 (1994) 213-216
61. El-Shabouri M.H. Positively charged nanoparticles for improving the oral bioavailability of ciclosporin-A. Int. J. Pharm. 249 (2002) 101-108
62. Wyvratt M.J., and Patchett P.A. Recent developments in the design of angiotensin-converting enzyme inhibitors. Med. Res. Rev. 5 (1985) 483-531
63. Brewster D., and Waltham K. TRH degradation rates vary widely between different animal species. Biochem. Pharmacol. 30 (1981) 619-622
64. David S., et al. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin. Exp. Immunol. 46 (1981) 649-652
65. Kipnes M., et al. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 26 (2003) 421-426
66. Jung T., et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. Eur. J. Pharm. Biopharm. 50 (2000) 147-160
67. Das D., and Lin S. Double-coated poly(butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci. 94 (2005) 1343-1353
68. Zhou S., et al. Study on biodegradable microspheres containing recombinant interferon-alpha-2α. J. Pharm. Pharmacol. 54 (2002) 1287-1292
69. Shojaei A.H. Buccal mucosa as a route for systemic drug delivery: a review. J. Pharm. Sci. 1 (1998) 15-30
70. Perrie Y., et al. Liposome-mediated DNA vaccination by the oral route. J. Liposome Res. 12 (2002) 185-197